Summary A human ovarian carcinoma, IGROV-1, was xenografted into different sites (i.p., s.c., i.v., and intrasplenically) in nude athymic female mice to investigate the pattern of antitumour efficacy of FAA and compare it to that of doxorubicin and cisplatin, two established cytotoxic drugs. Ascitic and lung-growing tumours totally failed to respond to FAA, whereas s.c. and liver-growing tumours were significantly growth inhibited. This pattern of activity differs from that achieved by the two conventional cytotoxic drugs, which were active against the IGROV-1 tumour growing in all of the tested sites. These studies indicate that cytotoxicity is not the major determinant of FAA antitumour efficacy even against human tumour xenografts. Moreover, the dramatic difference between the sensitivity of lung and liver tumour colonies demonstrates the great importance of the site of tumour growth for FAA efficacy.
Flavone acetic acid (FAA) is a synthetic flavonoid currently undergoing clinical trials. It has proved highly effective against a broad spectrum of subcutaneously growing murine tumours (Corbett et al., 1986; Plowman et al., 1986) and against orthotopic colonic tumours in mice . Preclinical pharmacology revealed a plasma concentration threshold for drug activity and toxicity in the mouse and dog (Zaharko et al., 1986) . Even though the plasma concentrations achievable in man were similar to those active in murine tumours (Kerr et al., 1987) , no responses were observed in a Phase II trial in which potentially therapeutic doses of FAA were delivered based on pharmacokinetic studies (Kaye et al., 1988) . The discrepancy between clinical and preclinical FAA activity might be due to specific differences in drug disposition and metabolism. A lower clearance of the drug in mice than in man (Cummings et al., 1989 ) and a high drug uptake into solid tumours in mice have been documented (Workman & Ward, 1989) .
Several studies support the hypothesis that FAA may act as a biological response modifier, and that its antitumour effects may be host-mediated (Smith et al., 1987; Ching & Baguley, 1987; Hornung et al., 1988; . Reduction of tumour blood flow by FAA has also been described (Bibby et al., 1989a; Evelhoch et al., 1988; Zwi et al., 1989 Bibby et al., 1987) . The site of growth may be critical for tumour sensitivity and some reports have indicated its importance in FAA efficacy in the treatment of murine models (Bibby et al., 1989b) .
In this study, the importance of the site of tumour growth was investigated for a human tumour xenografted in athymic mice. A human ovarian tumour, IGROV-1, was chosen for its ability to grow in different sites in nude athymic mice Table III ). After killing, a 15% solution of India ink in phosphate buffered saline (PBS) was injected into the bronchus of each mice. The removed lungs were bleached in Fekete's solution (Fekete, 1938) allowing the metastases to be counted easily as they formed discrete white nodules on the surface of the lung.
Experimental liver metastases Mice were inoculated in the spleen with 5 x I05 cells in I ml of medium according to Lafreniere and Rosenberg (1986 For s.c. growing murine tumours, the sensitivity has been possibly ascribed to a Tumour Necrosis Factor (TNF)-like action of FAA (Smith et al., 1987; Finlay et al., 1988) , and recently we have demonstrated a critical role of TNF in FAA activity against murine colon tumour # 26 (Pratesi et al., 1990) . However, the possibility that FAA antitumour efficacy on this human carcinoma is mediated through TNF seems unlikely, since haemorrhagic necrosis was not visible in the tumours 24 h after FAA treatment. Moreover, T cells represent an important component of FAA efficacy (Pratesi et al., 1990) and this mechanism may not be operating in nude mice, genetically lacking of T cells. Therefore, the basis of the activity of the drug against this human tumour xenografted s.c. in nude mice is unclear, but may be due to an effect on tumour blood flow as described in other tumour models (Evelhoch et al., 1988; Bibby et al., 1989a; Zwi et al., 1989) .
The most striking finding of this study was the dramatic difference in the efficacy of FAA against tumour cells growing in lungs or in the liver, whereas DX and DDP were active at both sites. The reasons for this difference remain unclear. Even though a cytotoxic effect of FAA per se seems unimportant in its antitumour efficacy, the high response achieved against liver colonies could be the result of metabolic activation of the drug to more cytotoxic compounds as observed in vitro (Chabot et al., 1989) . Differences in metabolism between mouse and man (Cummings et al., 1989) must be considered, and may explain the lack of activity in 17 patients with liver metastasis (Kerr et al., 1989) . As an alternative explanation of the different effect of FAA against liver and lung metastases, one might speculate that a critical threshold drug level at the tumour site is required for antitumour action. In fact, a higher peak level and area under the curve values , as well as a higher increase in NK activity in liver than in lungs of mice have been described. In conclusion, in contrast to the effects of two conventional cytotoxic drugs, which were effective against IGROV-1 ovarian tumour in all the examined sites, the activity of FAA was critically dependent on the site of tumour growth indicating that mechanisms other than a direct cytotoxicity are determinants of FAA activity even against human xenografts.
